Spring forward. Fall back. It��s an amusing little mnemonic relating to Daylight Saving Time, indicating that clocks are moved forward an hour in spring and back an hour in autumn. But there��s nothing funny about falling at any age.
Many people think falls are a normal part of aging. They��re not. And there are more than a few people and organizations who have set out to debunk this common myth and educate individuals of all ages about how serious falls can be and how to avoid them.
Now in its 10th year, ��National Falls Prevention Awareness Day�� (FPAD) is a nation-wide effort by the National Council On Aging (NCOA) and countless others to bring attention to this growing public health issue and how to prevent fall-related injuries among older adults.
Every year on the first day of fall, they celebrate FPAD to bring attention to this growing public health issue. Today is that day.
(Photo Courtesy of NCOA)NCOA 2015 Falls Free® Photo Contest Honorable Mention winner First Baptist Church of Glenarden; Landover, Maryland.
Best Stocks To Own Right Now: Discovery Communications, Inc.(DISCB)
Advisors' Opinion:- [By Max Byerly]
Discovery (NASDAQ:DISCB) announced its quarterly earnings results on Tuesday. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.13, Morningstar.com reports. Discovery had a negative net margin of 7.40% and a positive return on equity of 19.34%. The company had revenue of $2.31 billion for the quarter.
- [By Billy Duberstein]
You might think�Discovery Inc.'s (NASDAQ:DISCA) (NASDAQ:DISCK) (NASDAQ:DISCB) stations primarily feature nature videos and celebrity cooks, but did you know it's actually becoming a player on the international sports scene? While known for its namesake Discovery Channel and documentary brands such as The Learning Channel, HGTV, and the Food Network, Discovery has actually been in the sports business since 2012, when it first acquired a minority stake in European sports channel Eurosport. Discovery was apparently pleased enough with the channel's progress to buy 100% of Eurosport in July 2015, and that year, Eurosport won the exclusive rights to broadcast the Olympics in Europe from 2018-2022.
Best Stocks To Own Right Now: Internap Network Services Corporation(INAP)
Advisors' Opinion:- [By Stephan Byrd]
Internap Corp (NASDAQ:INAP) has received an average rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $28.00.
- [By Stephan Byrd]
Internap (NASDAQ:INAP) issued its quarterly earnings data on Thursday. The information technology services provider reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.13), MarketWatch Earnings reports. The business had revenue of $74.20 million for the quarter, compared to analyst estimates of $73.99 million. Internap had a negative return on equity of 271.76% and a negative net margin of 16.15%. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.02) earnings per share.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Internap (INAP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Best Stocks To Own Right Now: BioMarin Pharmaceutical Inc.(BMRN)
Advisors' Opinion:- [By Chris Lange]
BioMarin Pharmaceutical Inc.’s (NASDAQ: BMRN) first-quarter results are due late on Wednesday. The consensus forecast calls for a net loss of $0.18 per share and revenue of $348.57 million. The shares ended last week at $82.30. The consensus analyst target is $114.30. The 52-week trading range is $75.81 to $100.51.
- [By ]
BioMarin Pharmaceutical (Nasdaq: BMRN) is a leader in the orphan drug category (drugs used to treat rare diseases), which gives it extended protection and a longer sales trajectory versus other pharmaceuticals. The company is expected to bring its PKU treatment Pegvaliase to market this year to add significantly to sales and blockbusters Vosoritide and Valrox could come to market within the next two years.
- [By Ethan Ryder]
News articles about BioMarin Pharmaceutical (NASDAQ:BMRN) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.3333460791898 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
- [By Logan Wallace]
BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Jeffrey Robert Ajer sold 309 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, May 7th. The stock was sold at an average price of $85.96, for a total transaction of $26,561.64. Following the transaction, the executive vice president now directly owns 53,223 shares in the company, valued at approximately $4,575,049.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
- [By Todd Campbell]
I'm always on the lookout for fast-growing stocks to include in my retirement portfolio. Recently, I bought shares in Paycom Software, Inc.�(NYSE:PAYC), BioMarin Pharmaceutical (NASDAQ:BMRN), and 2U Inc. (NASDAQ:TWOU). Are these stocks right for your portfolio, too?�Read on to learn why I think these companies can deliver market-beating returns.
No comments:
Post a Comment